A National Cancer Institute-designated cancer center in Richmond, Va., VCU Massey Cancer Center conducts basic, translational, clinical and population sciences cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. Its 1,000-plus researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer.
November 17, 2020
Video
Leslie M. Randall, MD, MAS, discusses the unmet needs in platinum-resistant ovarian cancer.
September 19, 2019
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses ongoing challenges in the management of patients with metastatic HER2-positive breast cancer.
January 29, 2019
Article
Charles E. Geyer, Jrm, MD, discusses the clinical implications of the KATHERINE trial and the outlook for T-DM1 in patients with HER2-positive breast cancer.
January 22, 2019
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the impact of targeted agents in HER2-positive breast cancer.
December 29, 2018
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses pertuzumab in HER2-positive breast cancer.
December 11, 2018
Video
Charles E. Geyer, Jr, MD, professor of medicine, Virginia Commonwealth University School of Medicine; associate director for clinical research and Harrigan, Haw, Luck Families chair in Cancer Research, Massey Cancer Center, discusses the rationale and results of the phase III KATHERINE trial in HER2-positive breast cancer.